1999•Drug Development ResearchRequires access

US drug and biologic approvals in 1998

Bert Spilker, Stacey R. Fitzsimmons, Michael J. Horan

Open publisher page 5 citations

Abstract

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past 3 years have seen an unprecedented approval of 122 new drugs and 28 new biologics. Information is provided on the 39 new products approved by the FDA in 1998. Drug Dev. Res. 48:139–153, 1999. © 1999 Wiley-Liss, Inc.

About this research paper

What this paper is about

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past 3 years have seen an unprecedented approval of 122 new drugs and 28 new biologics. Information is provided on the 39 new products approved by the FDA in 1998. Drug Dev. Res. 48:139–153, 1999. © 1999 Wiley-Liss, Inc.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past 3 years have seen an unprecedented approval of 122 new drugs and 28 new biologics. Information is provided on the 39 new products approved by the FDA in 1998. Drug Dev. Res. 48:139–153, 1999. © 1999 Wiley-Liss, Inc.

Key concepts: Food and drug administration, Drug, Drug approval, Medicine, Pharmacology, Medical prescription, New drug application, Prescription drug

Related papers

Back to paper searchBrowse research topicsOriginal source
US drug and biologic approvals in 1998 — Research Paper | ScholarLens